# MTHERA PHARMA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mthera-pharma

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.mtherapharma.com/
- Total disclosed funding: $2.8M
- Latest round: Series A (Apr 9, 2021)
- Investors on record: 3

## About

Based in Seoul, South Korea, and founded in 2020 by co-founders Kim Sang-geon, Kim Sun-yeo, Lee Chung-hwan, Oh Myung-sook, and Jang Young-pyo, MTHERA PHARMA specializes in the research, development, and commercialization of pharmaceutical products. The company boasts a diverse pipeline of promising therapies targeting various therapeutic areas, including oncology, neurology, cardiovascular diseases, and rare disorders. In April 2021, MTHERA PHARMA raised KRW 3.2 billion in Series A funding from new investors Tony Investment, Sejong Venture Partners, and DAYLI Partners. As of 2023, the company's CEO is Min Won Shon.

The company offers natural drug products to treat chronic incurable diseases, such as parkinson’s disease, inflammatory bowel diseases, type 2 diabetes mellitus, and alzheimer’s diseases. MTHERA PHARMA uses the multicomponent multi-target (MCMT) approach to solve the limitations of single-target treatment for chronic incurable diseases. The platform uses an artificial intelligence (AI)-based big data system and a multi-omics analysis system that analyses virtual human body systems on a clinical basis. In addition, the firm's pipeline products include MT101 (Parkinson’s treatment, phase 3 clinical trial), MT102 (inflammatory bowel diseases), MT103 (Diabetic neuropathy treatment, phase 2), MT104 (alzheimer’s diseases), MT106 (Anti-Viral), and GCWB204 (cancer, phase 2).

## Funding rounds

- Series A, Apr 9, 2021, $2.8M — Sejong Venture Partners, DAYLI Partners, Tony Investment

## Investors

- Sejong Venture Partners — Series A
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A
- Tony Investment (https://capitalatlas.ai/funds/tony-investment) — Series A